CY1105699T1 - Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας - Google Patents

Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας

Info

Publication number
CY1105699T1
CY1105699T1 CY20061100913T CY061100913T CY1105699T1 CY 1105699 T1 CY1105699 T1 CY 1105699T1 CY 20061100913 T CY20061100913 T CY 20061100913T CY 061100913 T CY061100913 T CY 061100913T CY 1105699 T1 CY1105699 T1 CY 1105699T1
Authority
CY
Cyprus
Prior art keywords
alpha2
pharmaceutical compounds
receptor activity
new pharmaceutical
prodrug forms
Prior art date
Application number
CY20061100913T
Other languages
English (en)
Inventor
Tomi Jarvinen
Riku Niemi
Juhani Huuskonen
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of CY1105699T1 publication Critical patent/CY1105699T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση αφορά νέα προφάρμακα του MPV-2426 , μεθόδους δια την παρασκευή των αναφερθεισών μορφών προφαρμάκου , φαρμακευτικές ενώσεις οι οποίες περιέχουν τέτοιες μορφές προφαρμάκου και μεθόδους χρησιμοποιήσεως των μορφών προφαρμάκου.
CY20061100913T 2002-12-05 2006-07-03 Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας CY1105699T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20022159A FI20022159A0 (fi) 2002-12-05 2002-12-05 Uusia farmaseuttisia yhdisteitä
PCT/FI2003/000933 WO2004050635A2 (en) 2002-12-05 2003-12-05 Imidazol derivatives having affinity for alpha 2 receptors activity

Publications (1)

Publication Number Publication Date
CY1105699T1 true CY1105699T1 (el) 2010-12-22

Family

ID=8565048

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100913T CY1105699T1 (el) 2002-12-05 2006-07-03 Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας

Country Status (27)

Country Link
US (1) US7759496B2 (el)
EP (1) EP1572198B1 (el)
JP (1) JP4667042B2 (el)
KR (1) KR20050114603A (el)
CN (1) CN100560070C (el)
AT (1) ATE323484T1 (el)
BR (1) BR0317024A (el)
CA (1) CA2508335C (el)
CY (1) CY1105699T1 (el)
DE (1) DE60304741T2 (el)
DK (1) DK1572198T3 (el)
EA (1) EA008251B1 (el)
ES (1) ES2262031T3 (el)
FI (1) FI20022159A0 (el)
HR (1) HRP20050617B1 (el)
IL (1) IL168882A (el)
IS (1) IS2282B (el)
ME (1) ME00521B (el)
MX (1) MXPA05005963A (el)
NO (1) NO330392B1 (el)
NZ (1) NZ540466A (el)
PL (1) PL216530B1 (el)
PT (1) PT1572198E (el)
RS (1) RS52571B (el)
SI (1) SI1572198T1 (el)
WO (1) WO2004050635A2 (el)
ZA (1) ZA200504533B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
ATE478069T1 (de) 2005-08-25 2010-09-15 Schering Corp 3,4-dihydro-2h-benzoä1,4üoxazin- und 3,4-dihydro- 2h-benzoä1,4üthiazin-verbindungen als alpha2c- adrenorezeptor-antagonisten
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
WO2010042473A1 (en) 2008-10-07 2010-04-15 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
KR100646811B1 (ko) 1998-09-28 2006-11-17 오리온 코포레이션 척추내, 척수강내, 또는 경막외 투여용 약물 제조에서3-(1에이치-이미다졸-4-일메틸)-인단-5-올의 용도
EP1223931B1 (en) * 1999-10-29 2005-12-14 Orion Corporation Use of a imidazole derivative for the treatment or prevention of hypotension and shock
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7439268B2 (en) * 2003-07-18 2008-10-21 Idexx Laboratories Compositions containing prodrugs of florfenicol and methods of use

Also Published As

Publication number Publication date
ME00521B (me) 2011-10-10
JP4667042B2 (ja) 2011-04-06
DE60304741T2 (de) 2007-04-12
HRP20050617B1 (hr) 2013-07-31
EP1572198B1 (en) 2006-04-19
CN1735409A (zh) 2006-02-15
IS2282B (is) 2007-09-15
MXPA05005963A (es) 2005-08-18
FI20022159A0 (fi) 2002-12-05
KR20050114603A (ko) 2005-12-06
SI1572198T1 (sl) 2006-08-31
HRP20050617A2 (en) 2005-10-31
US20060178417A1 (en) 2006-08-10
DE60304741D1 (de) 2006-05-24
EP1572198A2 (en) 2005-09-14
NZ540466A (en) 2008-04-30
ATE323484T1 (de) 2006-05-15
RS52571B (en) 2013-04-30
ZA200504533B (en) 2006-03-29
BR0317024A (pt) 2005-10-25
US7759496B2 (en) 2010-07-20
DK1572198T3 (da) 2006-07-03
NO20053302L (no) 2005-07-05
CA2508335A1 (en) 2004-06-17
NO20053302D0 (no) 2005-07-05
JP2006509780A (ja) 2006-03-23
PL216530B1 (pl) 2014-04-30
EA008251B1 (ru) 2007-04-27
IL168882A (en) 2010-05-31
ES2262031T3 (es) 2006-11-16
IS7911A (is) 2005-06-23
NO330392B1 (no) 2011-04-04
CN100560070C (zh) 2009-11-18
AU2003302622A1 (en) 2004-06-23
WO2004050635A3 (en) 2004-09-02
PL377530A1 (pl) 2006-02-06
CA2508335C (en) 2011-09-13
PT1572198E (pt) 2006-08-31
WO2004050635A2 (en) 2004-06-17
EA200500922A1 (ru) 2005-12-29
RS20050428A (en) 2007-08-03

Similar Documents

Publication Publication Date Title
CY1119077T1 (el) Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων
SE0202241D0 (sv) Novel Compounds
CY1113757T1 (el) Παραγωγα πιπεριδινης και πιπεραζινης για τη θεραπεια ογκων
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
CY1109888T1 (el) Προφαρμακα των ενωσεων 2,4-πυριμιδινδιαμινης και οι χρησεις αυτων
CY1108101T1 (el) Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
CY1105337T1 (el) Πρωτοτυπες διυδροπτepιδινονες, μεθοδος για την παραγωγη τους και η χρηση τους ως φαρμακευτικα μεσα
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
CY1106076T1 (el) Παραγωγα γλυκοπυρανοσυλοξυβενζυλο βενζολιου και ιατρικες συνθεσεις που πepιεχουν τα ιδια
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
CY1110064T1 (el) Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
CY1111166T1 (el) Νεα παραγωγα 1,4-βενζοθειεπινο-1,1-διοξειδιου υποκατεστημενα με ριζες βενζυλιου, μεθοδοι διεργασιων για την παρασκευη τους, φαρμακα που περιεχουν αυτες τις ενωσεις και η χρηση τους
ATE447562T1 (de) Verstärker von glutamat-rezeptoren
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
CY1113533T1 (el) Ετεροαρυλο-υποκατεστημενα παραγωγα κυκλοεξυλο-1,4-διαμινης
CY1108529T1 (el) Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
CY1108447T1 (el) Προφαρμακο αμιδιου της γεμσιταβινης, οι συνθεσεις και η χρηση τους
EA200600197A1 (ru) Получение производных соединения 1,3-дифенилпроп-2-ен-1-он
ECSP045497A (es) "difenilazetidinonas sustituidas con grupos acidos, metodo para su producción, medicamentos que comprenden dichos compuestos y su uso"
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης